Exact Sciences (EXAS) shares soared roughly 20% on Thursday morning after Abbott (ABT) said it’s buying the molecular diagnostics firm in a deal that values it at $21 billion. Abbott is paying $105 for each EXAS shares, a significant premium on their previous close, as this transaction will grow its presence in the fast-growing cancer diagnostics market. More News from Barchart At the time of writing, Exact Sciences stock is up more than 160% versus its year-to-date low set in April. www.barchart.com ...